Drugs / Orforglipron
Orforglipron
also known as
LY3502970 · [14C]-LY3502970 · LY-3502970 HEMICALCIUM · ORFORGLIPRON CALCIUM · Orforglipron hemicalcium
Small molecule targets GLP1R via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FOUNDAYO | — | 2026-04-01 | fda.gov ↗ |
Trials 49 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 121 trials | ||||||
| Phase 1 | NCT06824051 | Feb 2025 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06692348 | Dec 2024 → Jun 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06704763 | Dec 2024 → Feb 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06440980 | Jun 2024 → Jun 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06370728 | May → Jul 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06186622 | Jan → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06085482 | Oct 2023 → Jan 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06023095 | Sep 2023 → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05936138 | Jul 2023 → Apr 2024 | impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05882032 | Jun 2023 → Nov 2024 | liver disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05841238 | Apr → Sep 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05573230 | Oct 2022 → Jan 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05469126 | Aug → Nov 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05313802 | May → Sep 2022 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05341089 | May → Sep 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05086445 | Nov 2021 → Sep 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05110794 | Nov 2021 → Feb 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05051566 | Sep 2021 → Apr 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04680767 | Mar → Jul 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04426474 | Oct 2020 → Jul 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03929744 | Jun 2019 → Nov 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07107334 | Apr 2026 → Nov 2028 expected | endometrial endometrioid adenocarcinoma | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT05051579 | Sep 2021 → Aug 2022 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05048719 | Sep 2021 → Sep 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT07668336 | Sep 2026 → Mar 2030 expected | type 2 diabetes mellitus | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07613307 | Jul 2026 → May 2027 expected | type 2 diabetes mellitus | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07241390 | Dec 2025 → Aug 2031 expected | atherosclerotic cardiovascular disease, chronic kidney disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07223593 | Oct 2025 → Jun 2028 expected | peripheral arterial disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07202884 | Sep 2025 → Mar 2028 expected | female stress incontinence | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07153471 | Sep 2025 → Apr 2028 expected | osteoarthritis | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06972472 | May 2025 → Aug 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06993792 | May 2025 → Aug 2027 expected | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06972459 | May 2025 → Aug 2027 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06948422 | Apr 2025 → Sep 2027 expected | hypertensive disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06948435 | Apr 2025 → Sep 2027 expected | hypertensive disorder, obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06952530 | Apr 2025 → Sep 2027 expected | hypertensive disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06672549 | Nov 2024 → Feb 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06672939 | Nov 2024 → Dec 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06649045 | Oct 2024 → Nov 2026 expected | obesity disorder, obstructive sleep apnea syndrome | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06584916 | Sep 2024 → Nov 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06192108 | Jan 2024 → Sep 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06109311 | Nov 2023 → Sep 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06010004 | Sep 2023 → Jun 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06045221 | Sep 2023 → Aug 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05971940 | Aug 2023 → Apr 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05931380 | Jul 2023 → Jun 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05869903 | Jun 2023 → Jul 2025 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05872620 | Jun 2023 → Aug 2025 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05803421 | Apr 2023 → Mar 2026 | cardiovascular disorder, chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 52 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | orforglipron | “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗34“Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction.” PMID 37351564 ↗ Jun 2023 “orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA)” PMID 38402332 ↗ Feb 2024 “Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.” PMID 38402332 ↗ Feb 2024 |
| Known as | [14C]-LY3502970 | “Participants received a single oral dose of 1 milligram (mg) LY3502970 followed six hours later by an intravenous (IV) dose of approximately 21 microgram (μg) of LY3502970...” NCT06085482 ↗ |
| Known as | LY-3502970 HEMICALCIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4446782 ↗ |
| Known as | LY3502970 | “A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)” NCT06948422 ↗20“A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity” NCT06972459 ↗ “A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes” NCT06993792 ↗ “A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities” NCT06672939 ↗ “orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA)” PMID 38402332 ↗ Feb 2024 |
| Known as | ORFORGLIPRON CALCIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL4446782 ↗ |
| Known as | Orforglipron hemicalcium | ChEMBL registry synonym — accepted as the source's own label CHEMBL4446782 ↗ |
| Action | Activate | “orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA)” PMID 38402332 ↗ Feb 2024 |
| Modality | Small molecule | “orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA)” PMID 38402332 ↗ Feb 2024 |
| Route | Oral | “Administered orally.” NCT03929744 ↗ |
| Target | GLP1R | “glucagon-like peptide-1 (GLP-1) receptor agonist” PMID 42120723 ↗ May 2026 |